CLRB CLRB
Company Profile ↓Company Overview
CLRB (CLRB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -50.20% |
| 6 Months: | -19.23% |
| 3 Months: | -20.75% |
| 1 Month: | -6.67% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 59.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.71M | -2.72M | -2.91M | -2.82M | -2.55M | -2.27M | -2.59M | -2.29M | -2.09M | -2.00M | -2.33M | -2.47M | -2.81M | -3.22M | -3.48M | -3.45M | -2.90M | -3.09M | -3.63M | -3.20M | -3.96M | -3.96M | -3.62M | -3.91M | -6.36M | -6.03M | -5.82M | -6.14M | -7.44M | -7.82M | -8.71M | -8.29M | -9.41M | -12.00M | -13.70M | -13.33M | -6.40M | -6.04M | -4.85M | -5.79M |
| Net Income | -3.45M | -2.06M | -1.32M | -2.94M | -2.09M | 324.02K | -2.30M | -2.29M | -1.86M | 824.56K | -2.13M | -2.29M | -2.89M | -3.12M | -3.47M | -3.48M | -2.92M | -3.01M | -3.62M | -3.19M | -3.90M | -3.96M | -3.61M | -3.91M | -6.36M | -6.03M | -5.82M | -6.14M | -7.44M | -7.81M | -7.19M | -10.18M | -17.52M | -26.64M | -919.37K | -14.66M | -6.60M | -5.45M | -4.44M | -5.65M |
| Diluted EPS | - | - | - | - | - | - | -3.04 | - | - | 0.91 | - | - | -0.24 | - | - | - | - | - | - | - | - | - | - | -0.15 | -0.13 | -1.14 | -0.97 | -1.00 | -1.22 | -1.28 | -0.76 | -0.90 | -1.55 | -0.91 | -5.43 | -12.13 | -4.30 | -3.39 | -1.41 | -1.33 |
| R&D Expense | 1.59M | 1.65M | 2.07M | 1.72M | 1.38M | 1.47M | 1.64M | 1.38M | 1.17M | 1.04M | 965.18K | 1.31M | 1.86M | 2.18M | 2.33M | 2.12M | 1.72M | 2.00M | 2.31M | 1.81M | 2.70M | 2.62M | 2.47M | 2.68M | 4.63M | 4.63M | 3.94M | 3.89M | 4.50M | 5.38M | 6.65M | 6.14M | 7.03M | 7.09M | 7.35M | 5.49M | 3.43M | 2.39M | 2.52M | 3.01M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | - | - | - | - | -4.19M | -7.04M | -8.75M | -12.40M | -9.89M | -8.76M | -9.45M | -13.60M | -13.33M | -14.18M | -15.29M | -24.13M | -28.81M | -38.96M | -51.78M | -22.98M |
| Net Income | -295.79K | -342.76K | -481.84K | -963.44K | -5.09M | -6.09M | -6.22M | -4.56M | -7.44M | -8.80M | -10.78M | -8.05M | -5.50M | -6.18M | -13.56M | -13.24M | -14.09M | -15.09M | -24.12M | -28.60M | -42.77M | -44.58M | -21.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.84 | -4.35 | -4.05 | -3.50 | -41.89 | -8.35 |
| R&D Expense | - | - | - | - | - | - | - | 2.98M | 3.60M | 5.12M | 6.86M | 5.96M | 5.16M | 4.75M | 9.47M | 6.84M | 9.00M | 10.14M | 17.59M | 19.22M | 27.27M | 26.14M | 11.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2002 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | 4.80M | 10.56M | 11.48M | 6.82M | 13.42M | 7.60M | 15.32M | 12.87M | 15.05M | 12.25M | 58.66M | 37.20M | 21.59M | 12.08M | 25.47M | 14.98M |
| Total Equity | 0 | 599.38K | 388.94K | 46.17K | 400.21K | 6.55M | 2.53M | 9.84M | 4.13M | 133.76K | 9.48M | 10.16M | 1.70M | 6.70M | 1.65M | 13.54M | 10.75M | 13.26M | 9.06M | 54.79M | 33.05M | 8.15M | -15.16M | 14.29M | 8.54M |
| Cash & Equivalents | 0 | - | - | - | - | - | - | - | 980.12K | 673.74K | 5.51M | 4.68M | 2.42M | 9.42M | 3.91M | 11.44M | 10.01M | 13.26M | 10.61M | 57.17M | 35.70M | 19.87M | 9.56M | 23.29M | 13.20M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 450.00K | 450.00K | 450.00K | 330.22K | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 1.32M | 5.12M | 6.72M | 5.95M | 1.78M | 2.12M | 1.79M | 3.19M | 3.86M | 4.16M | 6.08M | 25.85M | 9.80M | 5.06M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | 904.82K | 503.58K | 732.69K | 4.52M | 6.23M | 5.70M | 1.63M | 2.11M | 1.62M | 2.77M | 3.56M | 3.99M | 5.53M | 25.36M | 9.39M | 4.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.38M | -5.97M | -6.59M | - | - | - | -8.28M | -11.02M | -11.44M | -11.69M | -13.93M | -22.57M | -25.22M | -32.38M | -47.58M | -23.12M |
| Investing Cash Flow | -1.65K | 1.29M | -2.10M | - | - | - | -72.25K | -346.70K | -329.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K |
| Financing Cash Flow | 3.08M | 9.52M | 7.85M | - | - | - | 15.94M | 9.93M | 15.02M | 9.02M | 60.55M | 1.25M | 9.61M | 22.94M | 61.41M | 13.03M |
| Capital Expenditure | -1.65K | -118.41K | -97.69K | -147.81K | -29.57K | -58.47K | -72.25K | -346.70K | -384.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K |
| Free Cash Flow | -3.38M | -6.09M | -6.68M | - | - | - | -8.35M | -11.37M | -11.83M | -11.72M | -14.00M | -22.71M | -25.45M | -33.24M | -47.69M | -23.12M |
| Share Buybacks | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -76.1% | -742.3% | -120.4% | -14.7% | -201.5% | -61.9% | -150.7% | -3,409.2% | -78.4% | -86.6% | -634.4% | -120.2% | -333.1% | -45.6% | -126.1% | -99.8% | -155.6% | -27.5% | -73.0% | -350.8% | 282.1% | -311.9% | -255.2% |
| ROCE % | - | - | - | - | - | - | - | -107.6% | -70.0% | -81.5% | -540.9% | -137.6% | -462.6% | -69.0% | -126.4% | -99.2% | -149.5% | -27.8% | -72.7% | -179.4% | 293.3% | -321.9% | -224.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLRB
Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQRGxlZ2h1N0VFNUdUN3dZUnFrSEJzanZvVkUyTzNzaVJESk1xSmowUjRZVkIzaFZxSXpMSDJwLWtnM1U5ZkNDcU9yUVh4dHRrTFdSMWtzU2Iwc0syaXpTWUFDdkJTaElBNjVhOW1CRUhzS3ZiUWZuVjF5LWkyV0FNZ1NfRi1pYkMzRG9UN0…
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxONHZfMzRVZld5aTlQbl9UV2ZZUjNtckx2YzlCNUstLTV2ZkJfNkRkQVlLODBDVGdvYVNkaEtWOGJfbHFPVFIyak4wYVhTUENtM3owNmxiNldfR1ZjRmJLcll1T2hNT2Itd0pCRVhJZlhSaG5nUGlDWng5dlJTWXk4X1Bad0llb3FfVnNIMH…
CLRB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9ObTZRSWlrYUNyc2JqTTJjNWNWUG9tYzVDVFRHbU1EQmxNZzdSX2J0Tm1fb2hHeEEzdkV3QWNFTmlpYjN0WVJJcE5PNURBajJoZmRjWlRKWTVhSjlvZUtzSmdSaEpGWjFXVHM5Z2JYWlEwbHBfSDdTSk9R?oc=5" target="_blank">CLR…
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNdEhZWmxKUEx4TTVZSkU0bTlIVnN1bWJTT0p1WHhPOGMwRmhGYVpUMlpXVkI0Y25kYlQyQ3RXZ3RVRXpPbU9LNHZXWEVmM09jUVR0YlRGcy1kSVY1TlVUZ0JWNU8yZkg3OXJ6aVJjSl9Mb0ZNTkVSUUpNOXU0aUNFN2hNVVVIMkUweFBQSU…
CLRB|Cellectar Biosciences Inc|Price:2.595|Chg%:+0.025 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9TMXNNN0QzOW9aYXdsaVluYTQxVmcybzNlR0xJQk9FVUM5OFdrdGNDdnQ1eFRlVGxEUmU1b3cyRTZWQ3pkSnExYldRNHRjYjIzRnRMU3R6TkdZVkhjaTMyZHUxTE50ZkFtX3BKMFpn?oc=5" target="_blank">CLRB|Cellectar Bios…
Should I buy Cellectar Biosciences (CLRB) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5TU01Fb3g5VXozNnRuU3h5RDItcl9VeTg5OUVvVTRQYmxKSkJPS21TZDhfVDBOQmg5RTdpdmp5TTNKZjBGRFpQSW9heGtkYmRqUlE4dlZPZlpTeHR1X2Z2a2liRk1oMmdCM1JEZQ?oc=5" target="_blank">Should I buy Cellecta…
CLRB — Frequently Asked Questions
What is the current share price of CLRB?
As of 2026-08-05 17:25 PDT, CLRB trades at $2.52 on NASDAQ/NYSE. Its 52-week range is $2.23 to $6.17.
What is the P/E ratio of CLRB?
CLRB trades at a trailing price-to-earnings (P/E) ratio of -0.30.
Is CLRB a good stock to buy?
This page provides a data-driven analysis of CLRB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.